InMed Pharmaceuticals Inc. (TSE:IN – Get Free Report)’s stock price traded down 1.6% during trading on Monday . The company traded as low as C$4.13 and last traded at C$4.19. 17,035 shares were traded during mid-day trading, a decline of 42% from the average session volume of 29,552 shares. The stock had previously closed at C$4.26.
InMed Pharmaceuticals Stock Down 1.6 %
The stock has a market cap of C$33.73 million and a PE ratio of -2.77. The company has a quick ratio of 1.45, a current ratio of 2.13 and a debt-to-equity ratio of 8.48. The business’s 50-day moving average price is C$4.19.
InMed Pharmaceuticals Company Profile
InMed Pharmaceuticals Inc, a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain.
See Also
- Five stocks we like better than InMed Pharmaceuticals
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- 3 CEO-Led Turnaround Stocks You Can Still Buy
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- 3 Value Stocks You Can Buy Before They Become Big
- 5 Top Rated Dividend Stocks to Consider
- Chinese Stocks Stage Impressive Rebound
Receive News & Ratings for InMed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.